MAIA Reports Positive Efficacy Results From Phase II Trial for NSCLC

MAIA reports strong data from trial of 3L therapy in NSCLC - BioTuesdays

MAIA Biotechnology (NYSE American: MAIA) has announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorporating telomere targeting and immunogenicity, as a third-line (3L) therapy for patients with advanced non-small cell lung cancer (NSCLC). According to MAIA, initial data from the THIO-101 Part C 3L study showed a disease…

MAIA reports positive efficacy results from Phase II trial for NSCLC

MAIA Biotechnology has reported positive initial efficacy results from its Phase II THIO-101 trial, Part C, involving its lead candidate, ateganosine, as a third-line treatment for patients with advanced non-small cell lung cancer (NSCLC). Early data from the Part C studies report a disease…

Release - MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial - Channelchek

Open the article to view the coverage from channelchek.com